Xlear submits COVID-19 pre-EAU request with FDA regarding use of Xlear Nasal Spray to help in combating SARS-CoV-2
WASHINGTON — Xlear is filing a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA is a first step in seeking authorization of Xlear Nasal Spray as a new hygiene tool to help in combat the SARS-CoV-2 virus, the virus that causes COVID-19. Xlear’s Pre-EUA Request is based on